UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 303

Sortiert nach

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Journal of clinical oncology, 2015-08, Vol.33 (24), p.2617-2622

2015

Link zum Volltext

Verfügbarkeit prüfen

Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection

Journal of clinical oncology, 2012-07, Vol.30 (19), p.2327-2333

2012

Link zum Volltext

Verfügbarkeit prüfen

Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405

JNCI : Journal of the National Cancer Institute, 2022-03, Vol.114 (3), p.427-435

2022

Link zum Volltext

Verfügbarkeit prüfen

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

Journal of clinical oncology, 2009-07, Vol.27 (19), p.3141-3147

2009

Link zum Volltext

Verfügbarkeit prüfen

In response: Diabetes is a risk factor for the progression and prognosis of COVID‐19

Diabetes/metabolism research and reviews, 2020-10, Vol.36 (7), p.e3331-n/a

Blanke, Charles D.

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

Journal of clinical oncology, 2010-08, Vol.28 (22), p.3605-3610

2010

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

Journal of clinical oncology, 2008-02, Vol.26 (4), p.620-625

2008

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2009-03, Vol.373 (9669), p.1097-1104

2009

Link zum Volltext

Verfügbarkeit prüfen

Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence

Journal of the American College of Surgeons, 2012-07, Vol.215 (1), p.53

2012

Link zum Volltext

Verfügbarkeit prüfen

Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database

JNCI : Journal of the National Cancer Institute, 2021-11, Vol.113 (12), p.1693-1704

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Journal of clinical oncology, 2008-02, Vol.26 (4), p.626-632

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

Annals of surgical oncology, 2012-04, Vol.19 (4), p.1074-1080

2012

Link zum Volltext

Verfügbarkeit prüfen

Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

Journal of clinical oncology, 2006-10, Vol.24 (29), p.4764-4774

2006

Link zum Volltext

Verfügbarkeit prüfen

Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies

Journal of clinical oncology, 2023-04, Vol.41 (11), p.2020-2028

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

Journal of surgical oncology, 2009-01, Vol.99 (1), p.42-47

2009

Link zum Volltext

Verfügbarkeit prüfen

Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

Journal of clinical oncology, 2005-12, Vol.23 (34), p.8664-8670

2005

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies

Journal of clinical oncology, 2002-03, Vol.20 (6), p.1692-1703

2002

Link zum Volltext

Verfügbarkeit prüfen

S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma

Journal of clinical oncology, 2011-12, Vol.29 (34), p.4555-4560

2011

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)

Journal of thoracic oncology, 2012-05, Vol.7 (5), p.906-912

2012

Link zum Volltext

Verfügbarkeit prüfen

Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials

Journal of clinical oncology, 2011-07, Vol.29 (20), p.2781-2786

2011

Link zum Volltext

Verfügbarkeit prüfen

The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer

The oncologist (Dayton, Ohio), 2007-01, Vol.12 (1), p.38-50

2007

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Clinical cancer research, 2020-05, Vol.26 (10), p.2290-2296

2020

Link zum Volltext

Verfügbarkeit prüfen

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

Journal of clinical oncology, 2019-05, Vol.37 (14), p.1217-1227

2019

Link zum Volltext

Verfügbarkeit prüfen

The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials

JAMA oncology, 2016-07, Vol.2 (7), p.875

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 303

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(190)
Mit Volltextzugriff
(274)

Publikationsform

Artikel
(194)
Buchkapitel
(103)
Bücher
(3)
Reviews
(2)
Berichte
(1)

Sprache

Englisch
(302)
Japanisch
(23)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(141)
Science & Technology
(141)
Humans
(140)
Oncology
(130)
Female
(80)
Male
(78)
Middle Aged
(71)
Aged
(68)
Adult
(56)
Tumors
(41)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(38)
Aged, 80 And Over
(36)
Biological And Medical Sciences
(34)
Medical Sciences
(34)
Chemotherapy
(33)
Treatment Outcome
(29)
Imatinib Mesylate
(28)
Antineoplastic Agents - Therapeutic Use
(27)
Disease-Free Survival
(24)
Benzamides
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection

Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

In response: Diabetes is a risk factor for the progression and prognosis of COVID‐19

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence

Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies

S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma

Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)

Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials

The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials

Suchergebnisse filtern